NO2560611T3 - - Google Patents

Info

Publication number
NO2560611T3
NO2560611T3 NO11719211A NO11719211A NO2560611T3 NO 2560611 T3 NO2560611 T3 NO 2560611T3 NO 11719211 A NO11719211 A NO 11719211A NO 11719211 A NO11719211 A NO 11719211A NO 2560611 T3 NO2560611 T3 NO 2560611T3
Authority
NO
Norway
Application number
NO11719211A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42710544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2560611(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2560611T3 publication Critical patent/NO2560611T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
NO11719211A 2010-04-21 2011-04-19 NO2560611T3 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10160565 2010-04-21
EP11719211.2A EP2560611B1 (en) 2010-04-21 2011-04-19 "process for providing particles with reduced electrostatic charges"
PCT/EP2011/056227 WO2011131663A1 (en) 2010-04-21 2011-04-19 "process for providing particles with reduced electrostatic charges"

Publications (1)

Publication Number Publication Date
NO2560611T3 true NO2560611T3 (el) 2018-06-02

Family

ID=42710544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11719211A NO2560611T3 (el) 2010-04-21 2011-04-19

Country Status (26)

Country Link
US (3) US20110262543A1 (el)
EP (1) EP2560611B1 (el)
JP (1) JP5913289B2 (el)
KR (2) KR101863523B1 (el)
CN (1) CN102858320B (el)
AR (1) AR081540A1 (el)
AU (1) AU2011244384B2 (el)
BR (1) BR112012026804B1 (el)
CA (1) CA2796934C (el)
DK (1) DK2560611T3 (el)
ES (1) ES2658179T3 (el)
HK (1) HK1174570A1 (el)
HR (1) HRP20180488T1 (el)
HU (1) HUE038555T2 (el)
IL (1) IL222519B (el)
MX (1) MX2012012045A (el)
MY (1) MY163011A (el)
NO (1) NO2560611T3 (el)
PL (1) PL2560611T3 (el)
PT (1) PT2560611T (el)
RU (1) RU2580312C2 (el)
SG (1) SG184964A1 (el)
SI (1) SI2560611T1 (el)
TW (1) TWI530301B (el)
UA (1) UA111470C2 (el)
WO (1) WO2011131663A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501776A (zh) * 2011-02-17 2014-01-08 西普拉有限公司 甘罗铵与β2激动剂的组合物
DE102011102614A1 (de) * 2011-05-27 2012-11-29 Roland Nied Verfahren zum Betrieb einer Strahlmühle sowie Strahlmühle
EP2804583A1 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
WO2013109209A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising fluticasone
WO2013109215A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising formoterol
BR112014017481A8 (pt) 2012-01-25 2021-06-15 Chiesi Farm Spa formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação
GB201205632D0 (en) * 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
EP2836204B1 (en) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
WO2014106727A1 (en) * 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
LT3409270T (lt) 2013-07-11 2021-07-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta adrenerginį agentą, skirta vartoti įkvepiant
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
RS60299B1 (sr) 2014-09-09 2020-07-31 Vectura Ltd Formulacija koja obuhvata glikopirolat, postupak i uređaj
DK3689379T3 (da) 2015-11-16 2021-09-06 Chiesi Farm Spa Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
CN105891616B (zh) * 2016-06-15 2018-06-15 北京航空航天大学 一种研究带电颗粒与火焰相互作用的实验装置
WO2018018669A1 (en) * 2016-07-28 2018-02-01 Esd Technology Consulting & Licensing Co., Ltd. Static charge reduction system
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
PT3833964T (pt) * 2018-08-07 2023-08-17 Norton Waterford Ltd Aplicação de espetroscopia de raman para o fabrico de pós de inalação
US20220331244A1 (en) 2019-09-24 2022-10-20 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CA3189493A1 (en) 2020-08-14 2022-02-17 Brian Paul O'NEILL An inhalable formulation of fluticasone propionate and albuterol sulfate
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
CN115400103B (zh) * 2022-09-22 2023-11-24 苏州易合医药有限公司 一种多孔性呼吸颗粒及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas blancharjq
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
HU226671B1 (en) * 1997-03-20 2009-06-29 Schering Corp Preparation of powder agglomerates
EP1862164A3 (de) * 1998-11-13 2012-12-26 Jagotec AG Trockenpulver zur Inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
JP5698423B2 (ja) * 2000-06-27 2015-04-08 ベクトゥラ・リミテッド 医薬組成物で使用するための粒子の製造法
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
SI1386630T1 (sl) 2002-07-31 2006-10-31 Chiesi Farma Spa Inhalator za prasek
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
JP2007534693A (ja) * 2004-04-23 2007-11-29 サイデックス・インコーポレイテッド スルホアルキルエーテルシクロデキストリンを含有するｄｐｉ製剤
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
CN101490004B (zh) 2006-07-14 2012-01-11 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烯基醇的衍生物
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof

Also Published As

Publication number Publication date
SI2560611T1 (en) 2018-03-30
MX2012012045A (es) 2012-12-17
HUE038555T2 (hu) 2018-10-29
EP2560611A1 (en) 2013-02-27
BR112012026804B1 (pt) 2021-11-16
AR081540A1 (es) 2012-10-03
SG184964A1 (en) 2012-11-29
DK2560611T3 (en) 2018-02-26
MY163011A (en) 2017-07-31
CN102858320B (zh) 2014-10-29
JP2013525327A (ja) 2013-06-20
US20190216731A1 (en) 2019-07-18
KR101863523B1 (ko) 2018-05-31
UA111470C2 (uk) 2016-05-10
KR20130062268A (ko) 2013-06-12
JP5913289B2 (ja) 2016-04-27
IL222519B (en) 2018-03-29
AU2011244384A1 (en) 2012-11-15
PT2560611T (pt) 2018-02-07
CN102858320A (zh) 2013-01-02
IL222519A0 (en) 2012-12-31
RU2012145762A (ru) 2014-05-27
AU2011244384B2 (en) 2016-06-23
US20230364015A1 (en) 2023-11-16
PL2560611T3 (pl) 2018-05-30
TWI530301B (zh) 2016-04-21
TW201206498A (en) 2012-02-16
US20110262543A1 (en) 2011-10-27
KR20170118975A (ko) 2017-10-25
CA2796934A1 (en) 2011-10-27
ES2658179T3 (es) 2018-03-08
BR112012026804A2 (pt) 2016-07-12
EP2560611B1 (en) 2018-01-03
CA2796934C (en) 2018-11-20
WO2011131663A1 (en) 2011-10-27
RU2580312C2 (ru) 2016-04-10
HRP20180488T1 (hr) 2018-07-13
HK1174570A1 (en) 2013-06-14

Similar Documents

Publication Publication Date Title
BR112012031500A2 (el)
BR112012029986A2 (el)
BR112012028408A2 (el)
BR112012026492A2 (el)
BR112012024897A2 (el)
BR112012019354A2 (el)
BR112012025307A2 (el)
BR112012002126A2 (el)
BR112012026946A2 (el)
BR112012017960A2 (el)
BR112012025482A2 (el)
BR112013006400A2 (el)
BR112012031826A2 (el)
BR112012025577A2 (el)
BR112012023249A2 (el)
NO2560611T3 (el)
BR112012016456A2 (el)
BR112012025308A2 (el)
BR112012018256A2 (el)
BR112012027945A2 (el)
BR112012024872A2 (el)
BR112012023265A2 (el)
BR112012026403A2 (el)
BR112012022788A2 (el)
BR112013003284A2 (el)